The head of Laboratory Corporation of America Holdings' hospitals and health systems group will now lead the company's entire diagnostics segment.
Gary Huff is being promoted to CEO of LabCorp Diagnostics, one of the largest clinical laboratories in the country next to rival Quest Diagnostics. Burlington, N.C.-based LabCorp's other business segment is Covance Drug Development, a recently acquired contract research organization that conducts clinical trials for drug and biotechnology firms, among other drug development services.
Huff, a LabCorp veteran, will oversee a business that processes approximately 500,000 patient specimens daily and employs over 36,000 people around the world, including the U.S., Canada and the U.K. Huff will report to LabCorp CEO David King and sit on the company's executive committee.
Huff began his career at LabCorp and has served in a number of roles, including senior vice president of the company's North Atlantic Division and senior vice president of national toxicology testing. For part of his career, he served as CEO or COO at several smaller lab firms.
Huff's promotion is effective immediately.